Abstract
The introduction of PET(-CT) has brought about a major paradigm shift in the management of thyroid carcinoma, especially from the diagnostic standpoint. From the viewpoint of patient management, the areas where it has made significant impact include the following: (1) the detection of disease focus in patients with differentiated thyroid carcinoma with elevated Tg levels and negative radioiodine scan. When localized disease is identified with F-18 FDG–PET-CT, surgery or focused radiotherapy could be utilized to eradicate the tumor; (2) the localization of disease in patients of MTC with elevated serum calcitonin levels; (3) the detection of unsuspected focal F-18 FDG uptake in the thyroid in patients undergoing whole body F-18 FDG PET for a different indication. This would prompt a workup to rule out thyroid carcinoma. The use of I-124 is evolving at this time and has been of great promise with regard to (a) its better efficacy of lesion detection and (b) the ability to provide lesion-specific dosimetry. In addition, F-18 FDG PET appears to be of potential value in patients with thyroid lymphoma in making the initial diagnosis, monitoring therapeutic response, and assessing for residual disease and/or recurrence.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Similar content being viewed by others
References
Cohen, M.S., Arslan, N., Dehdashti, F., et al. (2001) Risk of malignancy in thyroid incidentalomas identified by fluorodeoxyglucose-positron emission tomography. Surgery 130(6), 941–6.
Kang, K.W., Kim, S.K., Kang, H.S., et al. (2003) Prevalence and risk of cancer of focal thyroid incidentaloma identified by 18F-fluorodeoxyglucose positron emission tomography for metastasis evaluation and cancer screening in healthy subjects. J Clin Endocrinol Metab 88(9), 4100–4.
Kim, T.Y., Kim, W.B., Ryu, J.S., et al. (2005) 18F-fluorodeoxyglucose uptake in thyroid from positron emission tomogram (PET) for evaluation in cancer patients: high prevalence of malignancy in thyroid PET incidentaloma. Laryngoscope 115(6), 1074–8.
Are, C., Hsu, J.F., Schoder, H., et al. (2007) FDG-PET detected thyroid incidentalomas: need for further investigation. Ann Surg Oncol 14(1), 239–47.
Kurata, S., Ishibashi, M., Hiromatsu, Y., et al. (2007) Diffuse and diffuse-plus-focal uptake in the thyroid gland identified by using FDG-PET: prevalence of thyroid cancer and Hashimoto’s thyroiditis. Ann Nucl Med 21(6), 325–30.
Chen, Y.K., Ding, H.J., Chen, K.T., et al. (2005) Prevalence and risk of cancer of focal thyroid incidentaloma identified by 18F-fluorodeoxyglucose positron emission tomography for cancer screening in healthy subjects. Anticancer Res 25(2B), 1421–6.
Yi, J.G., Marom, E.M., Munden, R.F., et al. (2005) Focal uptake of fluorodeoxyglucose by the thyroid in patients undergoing initial disease staging with combined PET/CT for non-small cell lung cancer. Radiology 236(1), 271–5.
Choi, J.Y., Lee, K.S., Kim, H.J., et al. (2006) Focal thyroid lesions incidentally identified by integrated 18FFDG PET/CT: clinical significance and improved characterization. J Nucl Med 47(4), 609–15.
Chu, Q.D., Connor, M.S., Lilien, D.L., et al. (2006) Positron emission tomography (PET) positive thyroid incidentaloma: the risk of malignancy observed in a tertiary referral center. Am Surg 72(3), 272–5.
King, D.L., Stack, B.C. Jr., Spring, P.M., et al. (2007) Incidence of thyroid carcinoma in fluorodeoxyglucose positron emission tomography-positive thyroid incidentalomas. Otolaryngol Head Neck Surg 137(3), 400–4.
Bogsrud, T.V., Karantanis, D., Nathan, M.A., et al. (2007) The value of quantifying 18F-FDG uptake in thyroid nodules found incidentally on whole-body PET-CT. Nucl Med Commun 28(5), 373–81.
Nam, S.Y., Roh, J.L., Kim, J.S., et al. (2007) Focal uptake of (18)F-fluorodeoxyglucose by thyroid in patients with nonthyroidal head and neck cancers. Clin Endocrinol (Oxf) 67(1), 135–9.
Boerner, A.R., Voth, E., Theissen, P., et al. (1998) Glucose metabolism of the thyroid in Graves’ disease measured by F-18-fluorodeoxyglucose positron emission tomography. Thyroid 8, 765–72.
Boerner, A.R., Voth, E., Theissen, P., et al. (2000) Glucose metabolism of the thyroid in autonomous goiter measured by F-18-FDG-PET. Exp Clin Endocrinol Diabetes 108, 191–6.
Karantanis, D., Bogsrud, T.V., Wiseman, G.A., et al. (2007) Clinical significance of diffusely increased 18F-FDG uptake in the thyroid gland. J Nucl Med 48, 896–901.
Basu, S., Li, G., Bural, G., Alavi, A. (2008) Fluorodeoxyglucose positron emission tomography (FDG-PET) and PET/computed tomography imaging characteristics of thyroid lymphoma and their potential clinical utility. Acta Radiol 16, 1–4.
Burguera, B., Gharib, H. (2000) Thyroid incidentalomas: prevalence, diagnosis, significance, and management. Endocrinol Metab Clin North Am 29(1), 187–203.
Nakhjavani, M.K., Gharib, H., Goellner, J.R., et al. (1997) Metastasis to the thyroid gland: a report of 43 cases. Cancer 79(3), 574–8.
Basu, S., Alavi, A. (2007) Metastatic malignant melanoma to the thyroid gland detected by FDG-PET imaging. Clin Nucl Med 32(5), 388–9.
van Tol, K.M., Jager, P.L., Piers, D.A., et al. (2002) Better yield of (18)fluorodeoxyglucose-positron emission tomography in patients with metastatic differentiated thyroid carcinoma during thyrotropin stimulation. Thyroid 12(5), 381–7.
Chin, B.B., Patel, P., Cohade, C., et al. (2004) Recombinant human thyrotropin stimulation of fluoro-d-glucose positron emission tomography uptake in well-differentiated thyroid carcinoma. J Clin Endocrinol Metab 89(1), 91–5.
Parkin, M.D., Pisani, P., Ferlay, J. (1999) Global cancer statistics. Cancer J Clin 49, 33–64.
Hundahl, S.A., Fleming, I.D., Fremgen, A.M., et al. (1998) A National Cancer Data Base report on 53,856 cases of thyroid carcinoma treated in the US, ’85–’95. Cancer 83, 2638–48.
Iwata, M., Kasagi, K., Misaki, T., et al. (2004) Comparison of whole-body 18F-FDG PET, 99mTc-MIBI SPECT, and post-therapeutic 131I-Na scintigraphy in the detection of metastatic thyroid cancer. Eur J Nucl Med Mol Imaging 31(4), 491–8.
Chung, J-K, So, Y., Lee, J.S., et al. (1999) Value of FDG-PET in papillary thyroid carcinoma with negative 131-I whole-body scan.J Nucl Med 40, 986–92.
Yeo, J.S., Chung, J.K., So, Y., et al. (2001) F-18-fluoro-deoxyglucose positron emission tomography as a presurgical evaluation modality for I-131 negative thyroid carcinoma patients with local recurrence in cervical lymph nodes. Head Neck 23, 94–103.
Nahas, Z., Goldenberg, D., Fakhry, C., et al. (2005) The role of positron emission tomography/computed tomography in the management of recurrent papillary thyroid carcinoma. Laryngoscope 115, 237–43.
Hall, N., Kloos, R.T. (2007) PET Imaging in differentiated thyroid cancer: where does it fit and how do we use it. Arq Bras Endocrinol Metabol 51(5), 793–805.
Urhan, M., Mavi, A., Alavi, A., Nanni, C. (2008) Positron emission tomography and thyroid cancer. PET Clin 2, 295–304.
Joensuu, H., Ahonen, A. (1987) Imaging of metastases of thyroid carcinoma with fluorine-18 fluorodeoxyglucose. J Nucl Med 28, 910–4.
Cohen, J.B., Kalinyak, J.E., McDougall, I.R. (2003) Modern management of differentiated thyroid cancer. Cancer Biother Radiopharm 18(5), 689–705.
Feine, U., Lietzenmayer, R., Hanke, J.P., Held, J., Wohrle, H., Muller-Schauenburg, W. (1996) Fluorine-18-FDG and iodine-131-iodide uptake in thyroid cancer. J Nucl Med 37, 1468–72.
Grünwald, F., Menzel, C., Bender, H., et al. (1997) Comparison of 18FDG-PET with 131iodine and 99mTc-sestamibi scintigraphy in differentiated thyroid cancer. Thyroid 7, 327–35.
Conti, P.S., Durski, J.M., Bacqai, F., Grafton, S.T., Singer, P.A. (1999) Imaging of locally recurrent and metastatic thyroid cancer with positron emission tomography. Thyroid 9, 797–804.
Schluter, B., Bohuslavizki, K.H., Beyer, W., Plotkin, M., Buchert, R., Clausen, M. (2001) Impact of FDG PET on patients with differentiated thyroid cancer who present with elevated thyroglobulin and negative 131I scan.J Nucl Med 42, 71–6.
Grunwald, F., Kalicke, T., Feine, U., et al. (1999) Fluorine-18 fluorodeoxyglucose positron emission tomography in thyroid cancer: results of a multicentre study. Eur J Nucl Med 26, 1547–52.
McDougal, I.R., Davidson, J., Segall, S.M. (2001) Positron emission tomography of the thyroid, with an emphasis on thyroid cancer. Nucl Med Commun 22, 485–92.
van Tol, K.M., Jager, P.L., Piers, D.A., et al. (2002) Better yield of (18)fluorodeoxyglucose positron emission tomography in patients with metastatic differentiated thyroid carcinoma during thyrotropin stimulation. Thyroid 715(12), 381–7.
Moog, F., Linke, R., Manthey, N., et al. (2000) Influence of thyroid-stimulating hormone levels on uptake of FDG in recurrent and metastatic differentiated thyroid carcinoma. J Nucl Med 41, 1989–95.
Petrich, T., Borner, A.R., Weckesser, E., et al. (2001) Follow-up of thyroid cancer patients using rhTSH: preliminary results. Nuklearmedizin 40, 7–14.
Palmedo, H., Bucerius, J., Joe, A., et al. (2006) Integrated PET/CT in differentiated thyroid cancer: diagnostic accuracy and impact on patient management. J Nucl Med 47, 616–24.
Zoller, M., Kohlfuerst, S., Igerc, I., et al. (2007) Combined PET/CT in the follow-up of differentiated thyroid carcinoma: what is the impact of each modality. Eur J Nucl Med Mol Imaging 34, 487–95.
Iagaru, A., Kalinyak, J.E., McDougall, I.R. (2007) F-18 FDG PET/CT in the management of thyroid cancer. Clin Nucl Med 32, 690–5.
Shammas, A., Degirmenci, B., Mountz, J.M., et al. (2007) 18F-FDG PET/CT in patients with suspected recurrent or metastatic well-differentiated thyroid cancer. J Nucl Med 48, 221–6.
Wang, W., Macapinlac, H., Larson, S.M., et al. (1999) [18F]-2-fluoro-2-deoxy-d-glucose positron emission tomography localizes residual thyroid cancer in patients with negative diagnostic (131)I whole body scans and elevated serum thyroglobulin levels. J Clin Endocrinol Metab 84, 2291–302.
Grünwald, F., Menzel, C., Bender, H., et al. (1998) Redifferentiation therapy-induced radioiodine uptake in thyroid cancer. J Nucl Med 39, 1903–6.
Schonberger, J., Ruschhoff, J., Grimm, D., et al. (2002) Glucose transporter-1 gene expression is related to thyroid neoplasm with an unfavorable prognosis: an immunohistochemical study. Thyroid 12, 747–54.
Lowe, V.J., Mullan, B.P., Hay, I.D., et al. (2003) 18F-FDG PET of patients with Hürthle cell carcinoma. J Nucl Med 44(9), 1402–6.
Robbins, R.J., Wan, Q., Grewal, R.K., et al. (2006) Real-time prognosis for metastatic thyroid carcinoma based on 2-[18F]fluoro-2-deoxy-d-glucose-positron emission tomography scanning. J Clin Endocrinol Metab 91, 498–505.
Reimer, S., Adler, L.P., Bloom, A.D. (1998) Prospective evaluation of PET-FDG in FNA indeterminate thyroid nodules. J Nucl Med 39, 123.
Geus-Oei, L.F., Pieters, G.F., Bonenkamp, J.J., et al. (2006) 18FFDG PET reduces unnecessary hemithyroidectomies for thyroid nodules with inconclusive cytologic results.J Nucl Med 47, 770–5.
Kim, J.M., Ryu, J.S., Kim, T.Y., et al. (2007) 18F-luorodeoxyglucosepositron emission tomography does not predict malignancy in thyroid nodules cytologically diagnosed as follicular neoplasm. J Clin Endocrinol Metab 92(5), 1630–4.
Kresnik, E., Gallowitsch, H.J., Mikosch, P., et al. (2003) Fluorine-18-fluorodeoxyglucose positron emission tomography in the preoperative assessment of thyroid nodules in an endemic goiter area. Surgery 133, 294–9.
Robbins, R.J., Hill, R.H., Wang, W., et al. (2000) Inhibition of metabolic activity in papillary thyroid carcinoma by a somatostatin analogue. Thyroid 10, 177–83.
Erdi, Y.E., Macapinlac, H.A., Larson, S.M., et al. (1999) Radiation dose assessment for I-131 therapy of thyroid cancer using I-124 PET imaging. Clin Positron Imaging 2, 41–6.
Schirrmeister, H., Guhlman, A., Elsner, K., et al. (1999) Sensitivity in detecting osseous lesions depends on anatomic localization: planar bone scintigraphy versus 18-F PET. J Nucl Med 40, 1623–9.
Eschmann, S.M., Reischl, G., Bilger, K., et al. (2002) Evaluation of dosimetry of radioiodine therapy in benign and malignant thyroid disorders by means of iodine-124 and PET. Eur J Nucl Med Mol Imaging 29, 760–7.
Pentlow, K.S., Graham, M.C., Lambrecht, R.M., et al. (1991) Quantitative imaging of I-124 using positron emission tomography with applications to radioimmunodiagnosis and radioimmunotherapy. Med Phys 18, 357–66.
Pentlow, K.S., Graham, M.C., Lambrecht, R.M., et al. (1996) Quantitative imaging of iodine-124 with PET. J Nucl Med 37, 1557–62.
Rault, E., Vandenberghe, S., Van Holen, R., et al. (2007) Comparison of image quality of different iodine isotopes (I-123, I-124, and I-131). Cancer Biother Radiopharm 22, 423–30.
Freudenberg, L.S., Antoch, G., Jentzen, W., et al. (2004) Value of I-124-PET/CT in staging of patients with differentiated thyroid cancer. Eur Radiol 14, 2092–8.
Freudenberg, L.S., Jentzen, W., Gorges, R., et al. (2007) I-124-PET dosimetry in advanced differentiated thyroid cancer: therapeutic impact. Nuklearmedizin 46, 121–8.
Freudenberg, L.S., Jentzen, W., Marlowe, R.J., et al. (2007) 124-iodine positron emission tomography/computed tomography dosimetry in pediatric patients with differentiated thyroid cancer. Exp Clin Endocrinol Diabetes 115, 690–3.
Sgouros, G., Kolbert, K.S., Sheikh, A., et al. (2004) Patient-specific dosimetry for I-131 thyroid cancer therapy using I-124 PET and 3-dimensional-internal dosimetry (3D-ID) software. J Nucl Med 45, 1366–72.
Kolbert, K.S., Pentlow, K.S., Pearson, J.R., et al. (2007) Prediction of absorbed dose to normal organs in thyroid cancer patients treated with I-131 by use of I-124 PET and 3-dimensional internal dosimetry software.J Nucl Med 48, 143–9.
Ansell, S.M., Grant, C.S., Habermann, T.M. (1999) Primary thyroid lymphoma. Semin Oncol 26, 316–23.
Honing, M.L., Seldenrijk, C.A., de Maat, C.E. (1998) Primary thyroid lymphoma. Neth J Med 52, 75–8.
Derringer, G.A., Thompson, L.D., Frommelt, R.A., et al. (2000) Malignant lymphoma of the thyroid gland: a clinicopathologic study of 108 cases. Am J Surg Pathol 24, 623–39.
Ruggiero, F.P., Frauenhoffer, E., Stack, B.C. (2005) Thyroid lymphoma: a single institution’s experience. Otolaryngol Head Neck Surg 133, 888–96.
Kossev, P., Livolsi, V. (1999) Lymphoid lesions of the thyroid: review in light of the revised European–American lymphoma classification and upcoming World Health Organization classification. Thyroid 9, 1273–80.
Lin, E.C. (2007) FDG PET/CT for assessing therapy response in primary thyroid lymphoma. Clin Nucl Med 32(2), 152–3.
Brandt-Mainz, K., Muller, S.P., Gorges, R., et al. (2000) The value of F-18 FDG PET in patients with medullary thyroid cancer. Eur J Nucl Med 27, 490–6.
Szakall, S. Jr., Esik, O., Balzik, G., et al. (2002) F-18-PET detection of lymph node metastases in medullary thyroid carcinoma.J Nucl Med 43(1), 66–71.
de Groot, J.W., Links, T.P., Jager, P.L., et al. (2004) Impact of F-18 fluoro-2-deoxy-d-glucose positron emission tomography (FDG-PET) in patients with biochemical evidence of recurrent or residual medullary thyroid cancer. Ann Surg Oncol 11(8), 786–94.
Rubello, D., Rampin, L., Nanni, C., et al. (2008) The role of 18F-FDG PET/CT in detecting metastatic deposits of recurrent medullary thyroid carcinoma: a prospective study. Eur J Surg Oncol 34(5), 581–6.
Musholt, T.J., Musholt, P.B., Dehdashti, F., et al. (1997) Evaluation of fluorodeoxyglucose-positron emission tomographic scanning and its association with glucose transporter expression in medullary thyroid carcinoma and pheochromocytoma: a clinical and molecular study. Surgery 122, 1049–60.
Koopmans, K.P., de Groot, J.W., Plukker, J.T., et al. (2008) 18F-dihydroxyphenylalanine PET in patients with biochemical evidence of medullary thyroid cancer: relation to tumor differentiation. J Nucl Med 49(4), 524–31.
Hoegerle, S., Ghanem, N., Altehoefer, C., et al. (2003) 18F-DOPA positron emission tomography for the detection of glomus tumours. Eur J Nucl Med Mol Imaging 30, 689–94.
Beuthien-Baumann, B., Strumpf, A., Zessin, J., et al. (2007) Diagnostic impact of PET with 18F-FDG, 18F-DOPA and 3-O-methyl-6-[18F]fluoro-DOPA in recurrent or metastatic medullary thyroid carcinoma. Eur J Nucl Med Mol Imaging 34, 1604–9.
Grewal, R.K., Lubberink, M., Pentlow, K.S., Larson, S.M. (2007) The Role of Iodine-124-Positron Emission Tomography Imaging in the Management of Patients with Thyroid Cancer. PET Clinics 2(3), 313–20.
Urhan, M., Alavi, A., Nanni, C. (2007) The Evolving Role of Positron Emission Tomography in Patients with Medullary Thyroid Carcinoma. PET Clinics 2(3), 305–11.
Chen, W., Li, G., Parsons, M., Zhuang, H., Alavi, A. (2007) Clinical Significance of Incidental Focal Versus Diffuse Thyroid Uptake on FDG-PET Imaging. PET Clinics 2(3), 321–29.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2011 Humana Press
About this protocol
Cite this protocol
Basu, S., Urhan, M., Rosenbaum, J., Alavi, A. (2011). PET and PET/CT in the Management of Thyroid Cancer. In: Juweid, M., Hoekstra, O. (eds) Positron Emission Tomography. Methods in Molecular Biology, vol 727. Humana Press. https://doi.org/10.1007/978-1-61779-062-1_12
Download citation
DOI: https://doi.org/10.1007/978-1-61779-062-1_12
Published:
Publisher Name: Humana Press
Print ISBN: 978-1-61779-061-4
Online ISBN: 978-1-61779-062-1
eBook Packages: Springer Protocols